CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The grants are expected to be received over the next three years, commencing March 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Recall does not include any metabolic deficiency nutrition formulas
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Subscribe To Our Newsletter & Stay Updated
